HAIFA, Israel, Feb. 28, 2024 - Pluri Inc. a leading biotechnology company, has recently shared an update from its CEO and President, Yaky Yanay, highlighting the company’s achievements and outlining its goals for the year 2024. Despite recording a cumulative net loss of $24 million during the 12 months ending in the second quarter of 2024, Pluri Inc. remains optimistic about its position in the market.
One noteworthy aspect mentioned by the CEO is Pluri Inc.’s performance in the stock market. Currently, the company’s stock is trading on the NASDAQ at 2.6% above its 52-week average. This positive market performance demonstrates investor confidence in Pluri Inc. and indicates potential growth opportunities in the near future.
Although the company experienced a net loss over the past year, Yaky Yanay emphasizes that this setback should not overshadow Pluri Inc.’s commitment to innovation and its efforts across various industries. Pluri Inc. remains focused on advancing its biotechnology solutions, contributing to significant developments within the sector.
Pluri Inc. has been actively pursuing breakthroughs in the healthcare industry, particularly in the field of biotechnology. The company’s primary goal is to create innovative solutions that address unmet medical nee
Comments